AZD#

Related by string. * * AZD# ARRY . AZD# ARRY # . AZD# TC . AstraZeneca AZD# *

Related by context. All words. (Click for frequent words.) 68 elotuzumab 67 otelixizumab 67 PXD# 67 ATL# [001] 66 enzastaurin 66 pertuzumab 66 PDE4 inhibitor 66 BAY #-# 66 Archexin 66 receptor tyrosine kinase inhibitor 66 MEK inhibitor 66 R#/MEM # 65 phase IIb clinical 65 MAP# 65 PF # [001] 65 registrational trial 65 MDV# 65 CCX# 65 MGCD# [001] 65 GSK# [001] 64 Panzem R NCD 64 Phase Ib study 64 Dapagliflozin 64 INCB# [003] 64 HGS# 64 TELINTRA 64 orally bioavailable 64 Traficet EN 64 Dasatinib 64 HGS ETR1 64 INCB# [001] 64 solanezumab 64 mecamylamine 64 Zolinza 64 OXi# 64 Azixa 64 IMC A# 64 Troxatyl 64 Panzem R 64 EOquin 64 PS# [001] 63 PEG PAL 63 Fulvestrant 63 BRAF inhibitor 63 MEK inhibitors 63 Azedra 63 ELND# 63 Bicifadine 63 AEGR 63 Amrubicin 63 histone deacetylase HDAC inhibitor 63 Iloperidone 63 JAK inhibitor 63 albinterferon alfa 2b 63 axitinib 63 rNAPc2 63 pomalidomide 63 Vandetanib 63 oral prodrug 63 Mipomersen 63 investigational compound 63 lomitapide 63 AZD# TC 63 Triolex 63 Laquinimod 63 lintuzumab 63 ixabepilone 63 MGd 63 ISIS # 63 MAGE A3 ASCI 63 teriflunomide 63 tyrosine kinase inhibitor 63 Nanobody 63 Vitaxin 63 LAF# 62 Synavive 62 Phase IIa trials 62 atrasentan 62 diabetic neuropathic pain 62 valopicitabine 62 JAK inhibitors 62 AEG# 62 gefitinib Iressa 62 Phase 2b clinical trials 62 6R BH4 62 AQ4N 62 eltrombopag 62 Darusentan 62 phase Ib 62 darapladib 62 Alzhemed TM 62 olaparib 62 Pimavanserin 62 HGS ETR2 62 forodesine 62 Ambrisentan 62 metaglidasen 62 BCX# 62 Perifosine 62 HspE7 62 PRX # 62 Xanafide 62 Phase IIa trial 62 investigational humanized monoclonal antibody 62 Vilazodone 62 tezampanel 62 kinase inhibitor 62 Phenoptin 62 eniluracil 62 PRT# 62 ENMD # 62 PLK1 SNALP 62 nalbuphine ER 62 CR# vcMMAE 62 cangrelor 62 AZILECT R 62 elagolix 62 LY# [003] 62 mertansine 62 decitabine 62 Phase Ib 62 GAMMAGARD 62 HCD# [002] 62 ANYARA 62 Sorafenib 62 HuMax CD# 62 SCH # 61 IAP inhibitor 61 Allovectin 7 R 61 PARP inhibitor 61 sodium glucose cotransporter 61 Actilon 61 volociximab 61 mapatumumab 61 cannabinor 61 phase IIa clinical 61 angiogenesis inhibitor 61 ASA# 61 Carfilzomib 61 glufosfamide 61 GSK# [002] 61 TRIOLEX 61 IMA# 61 TBC# 61 Ocrelizumab 61 CA4P 61 Denufosol 61 safinamide 61 investigational monoclonal antibody 61 Phase 2a trial 61 apremilast 61 NGX# 61 ZD# [001] 61 RG# [001] 61 ELACYT 61 Zybrestat 61 dimebon 61 Bortezomib 61 SILENOR TM 61 daclizumab 61 Zoraxel 61 phase IIa 61 LymphoStat B 61 Aflibercept 61 Amigal 61 CoFactor 61 KRN# 61 HuMax CD4 61 PEGylated Fab fragment 61 tanespimycin 61 tremelimumab 61 ocrelizumab 61 GRN#L 61 HuLuc# 61 Targretin 61 Bevacizumab 61 Telintra 61 Tasimelteon 61 TG# [003] 61 PROMACTA 61 sorafenib Nexavar 61 Phase IIb trials 61 Debio 61 iloperidone 61 Androxal TM 61 Clolar ® 61 Phase Ib clinical 61 IMGN# 61 Allovectin 7 61 bapineuzumab 61 custirsen 61 Serdaxin 61 tasimelteon 61 atacicept 61 Ixempra 61 novel histone deacetylase 61 VAPRISOL 61 Phase 1b trial 61 Phase 2b trial 61 PEG SN# 61 Amplimexon 61 abiraterone acetate 61 fosbretabulin 60 cediranib 60 TACI Ig 60 GALNS 60 tarenflurbil 60 APD# 60 OvaRex R 60 ruxolitinib 60 Spiegelmer ® 60 teplizumab 60 PKC# 60 R#/MEM 60 Asentar 60 #D#C# 60 regorafenib 60 Neuradiab 60 Phase Ib clinical trials 60 Plicera 60 Pralatrexate 60 XL# [003] 60 Sapacitabine 60 vorinostat 60 cilengitide 60 Bezielle 60 bortezomib Velcade 60 lintuzumab SGN 60 Elesclomol 60 Pertuzumab 60 neratinib 60 deforolimus 60 Zalbin 60 vidofludimus 60 NVA# 60 T DM1 60 selective modulator 60 IIa trial 60 mTOR inhibitor 60 BMS # 60 nab paclitaxel 60 Factor Xa 60 aflibercept 60 favorable pharmacokinetic profile 60 Phase #b/#a trial 60 PSN# [002] 60 INC# 60 TRC# 60 SAR# [004] 60 bosutinib 60 Pemetrexed 60 vicriviroc 60 IL# PE#QQR 60 UPLYSO 60 vandetanib 60 ASONEP 60 adalimumab Humira 60 incyclinide 60 Syncria 60 FTY# 60 Symadex 60 TOCOSOL Paclitaxel 60 YONDELIS 60 NP2 Enkephalin 60 Preclinical studies suggest 60 Tarceva TM 60 baminercept 60 Panzem 60 orally administered inhibitor 60 Annamycin 60 bicifadine 60 efficacy endpoint 60 pharmacodynamic PD 60 Fibrillex TM 60 CB2 selective receptor agonist 60 bendamustine 60 TMC# [002] 60 XmAb# 60 BZL# 60 imetelstat 60 dacetuzumab 60 INCB# [002] 60 sunitinib 60 docetaxel Taxotere R 60 pralatrexate 60 proteasome inhibitor 60 Imprime PGG 60 gemcitabine Gemzar ® 60 KNS # 60 CEQ# 60 Orazol 60 Tyrima 60 tocilizumab 60 phase IIb trial 60 Desmoteplase 60 SILENOR 60 LY# [002] 60 ZOLINZA 60 QLT# 60 huC# DM4 60 SRT# [003] 60 TRO# 60 RhuDex TM 60 Sym# 60 Exelixis compounds 60 RH1 60 figitumumab 60 selective androgen receptor modulator 60 motesanib 60 HDAC inhibitor 60 Rasagiline 60 THR beta agonist 60 CRx 60 Onconase 60 Phase 2b clinical 60 teduglutide 60 Cannabinor 60 Elagolix 60 mGluR2 NAM 60 RhuDex ® 60 polymerase inhibitor 60 ALN TTR 60 CORT # 60 Golimumab 60 Xinlay 60 Nexavar ® 60 MNTX 60 S/GSK# 60 phase IIb 59 bevacizumab Avastin 59 Lu AA# 59 #ME# 59 PEG Interferon lambda 59 GW# [003] 59 CYT# 59 Gemcitabine 59 Omnitarg 59 Puricase 59 Aurora kinase inhibitor 59 EndoTAG TM -1 59 betrixaban 59 Fx #A 59 ProSavin 59 Romidepsin 59 thymalfasin 59 alvespimycin 59 preclinically 59 iniparib 59 temsirolimus 59 Promacta 59 Trastuzumab 59 Posiphen 59 Cloretazine R VNP#M 59 Clolar 59 Clonicel 59 erlotinib Tarceva 59 interferon gamma 1b 59 talactoferrin 59 azacitidine 59 JAK1 59 Abiraterone acetate 59 vosaroxin 59 TKM ApoB 59 tubulin inhibitor 59 RhuDex 59 TPI ASM8 59 glatiramer acetate 59 pharmacokinetics PK 59 ataluren 59 tiapamil 59 Aplidin 59 IRX 2 59 Enzastaurin 59 cetuximab Erbitux 59 Lenalidomide 59 Phase IIb trial 59 blinatumomab 59 Ozarelix 59 Erlotinib 59 HQK 59 HuMax EGFr 59 mGluR5 NAM 59 Dacogen injection 59 liposomal doxorubicin 59 OvaRex ® MAb 59 Preclinical studies 59 pradefovir 59 Maraviroc 59 FM VP4 59 vascular disrupting agents 59 urocortin 2 59 PNP inhibitor 59 rotigotine 59 confirmatory Phase III 59 reslizumab 59 Oral NKTR 59 HCV protease 59 Milnacipran 59 SERMs 59 Vidaza azacitidine 59 Aliskiren 59 iSONEP 59 VEGF receptor 59 novel VDA molecule 59 alvimopan 59 Corlux 59 FOLOTYN ® 59 HSP# inhibitor 59 Phenserine 59 visilizumab 59 gamma secretase inhibitor 59 CTLA 4 59 LEP ETU 59 ezogabine 59 midstage clinical 59 TLK# 59 EGFr 59 Gefitinib 59 guanfacine extended release 59 ganetespib 59 Diamyd ® 59 Hsp# Inhibitor 59 febuxostat 59 Factor VIIa 59 GFT# 59 vascular disrupting agent 59 EGS# 59 TELCYTA 59 belinostat 59 Zerenex 59 Phase IIB 59 pharmacodynamic effects 59 ramelteon 59 ICA # 59 generation antisense inhibitor 59 sapacitabine 59 Otelixizumab 59 generation purine nucleoside 59 Squalamine 59 TYKERB 59 multi kinase inhibitor 59 epothilone 59 eprotirome 59 obatoclax 59 Aclidinium 59 mipomersen 59 Phase 2b study 59 Tanespimycin 59 Vidofludimus 59 MetMAb 59 cathepsin K inhibitor 59 OMP #M# 59 liposomal formulation 59 IgG1 monoclonal antibody 59 dexpramipexole 59 torsemide ER 59 GV# [001] 59 goserelin 59 immunotherapeutic agent 59 Gabapentin GR 59 denufosol 59 Angiolix 59 fenofibric acid 59 canagliflozin 59 Clofarabine 59 orBec 59 Pradefovir 59 DermaVir Patch 59 Irinotecan 59 dasatinib Sprycel ® 59 dirucotide 59 Anticalin R 59 Omacetaxine mepesuccinate 59 antiplatelet agent 59 proteasome inhibitors 59 dose cohort 59 ularitide 59 VEGFR2 59 YERVOY 59 Ereska 59 UVIDEM 59 ALN PCS 59 PI3K inhibitor 59 CIMZIA TM 59 Nuvion 59 PDX pralatrexate 59 Naproxcinod 59 Temsirolimus 59 ALGRX 58 low dose cytarabine 58 CCR2 58 NPC 1C 58 MAXY alpha 58 humanized monoclonal antibody 58 dose cohorts 58 NUVIGIL 58 vemurafenib 58 #mg dose [001] 58 TREANDA 58 investigational therapies 58 Ofatumumab 58 riociguat 58 Phase #b/#a 58 Omacetaxine 58 VA# [002] 58 anti angiogenic agent 58 MAXY G# 58 Ceflatonin 58 gemcitabine Gemzar 58 etanercept 58 QVA# 58 anti angiogenic 58 seliciclib 58 tecarfarin 58 Safinamide 58 PLX# 58 Capesaris 58 HER2 positive metastatic breast 58 Ixabepilone 58 PF # [002] 58 Fampridine 58 PARP inhibitors 58 pan HDAC inhibitor 58 Blinatumomab 58 Torisel 58 PEGPH# 58 aplindore 58 GAP #B# 58 Ophena TM 58 Guanilib 58 investigational drug 58 Hycamtin 58 Emselex 58 tolerated dose MTD 58 tyrosine kinase inhibitors 58 CCR5 antagonist 58 Genasense 58 maraviroc 58 BEMA TM Fentanyl 58 Phase IIb 58 Rebif ® 58 humanized anti 58 muraglitazar 58 thalidomide Thalomid 58 Liraglutide 58 biologic therapy 58 NATRECOR R 58 OncoVEX GM CSF 58 fostamatinib 58 Aurexis 58 refractory chronic lymphocytic 58 TLR9 agonists 58 ofatumumab 58 Telcyta 58 DOS# 58 Glypromate 58 mGluR5 antagonists 58 dasatinib 58 L BLP# 58 docetaxel chemotherapy 58 AVE# 58 EGFR inhibitors 58 Neurodex 58 methylnaltrexone 58 Phase IIb clinical trials 58 angiotensin receptor blocker ARB 58 Rotigotine 58 maximally tolerated dose 58 Cloretazine VNP#M 58 Phase IIa clinical 58 AVN# [001] 58 latrepirdine 58 efficacy endpoints 58 targeted radiotherapeutic 58 galiximab 58 metastatic hormone refractory 58 SNT MC# 58 DACH platinum 58 AP# [003] 58 Viprinex 58 Ticagrelor 58 veltuzumab 58 IGF 1R 58 potent inhibitor 58 APOPTONE 58 GSK # 58 SGX# 58 abiraterone 58 Azedra TM 58 dosing cohort 58 SinuNase 58 DXL# 58 sulodexide 58 CDK inhibitor 58 Chemophase 58 celgosivir 58 Insegia 58 Phase IIIb clinical 58 vilazodone 58 HCV protease inhibitor 58 somatostatin analogue 58 Icatibant 58 Tesetaxel 58 SUTENT 58 romidepsin 58 selective androgen receptor modulators 58 PRTX 58 RGB # 58 TLR9 agonist 58 Eltrombopag 58 Olaparib 58 FOLFIRI 58 entinostat 58 velafermin belinostat 58 midstage trials 58 immunomodulator 58 Androxal ® 58 sunitinib malate 58 DEB# 58 plasma kallikrein inhibitor 58 pharmacodynamic 58 Valdoxan 58 pegylated interferons 58 squalamine 58 Apoptone 58 TH# [003] 58 AZILECT ® 58 Lapatinib 58 Neuvenge 58 Kuvan 58 pharmacodynamic properties 58 Phase 1b 58 lapatinib Tykerb 58 RDEA# 58 zileuton 58 Ostarine 58 radiation sensitizer 58 Glufosfamide 58 PEG IFN 58 FOLOTYN 58 viral kinetics 58 CDP# 58 Epratuzumab 58 cell lymphoma CTCL 58 anti leukemic 58 immunomodulatory 58 IAP inhibitors 58 tasocitinib 58 Hedgehog inhibitor 58 JAK2 inhibitors 58 rHuPH# 58 RSD# oral 58 Relovair 58 ThermoDox R 58 Aptivus ® 58 Silodosin 58 RELOVAIR ™ 58 arzoxifene 58 Aurora kinase 58 generation antisense 58 CD3 monoclonal antibody 58 tipifarnib 58 Crizotinib 58 anticancer agent 58 Firazyr 58 Locteron 58 ONTAK 58 BNC# 58 Stedivaze 58 XP# XP# 58 Nanobody ® 58 ZACTIMA 58 MGCD# [002] 58 delta isoform 58 velafermin 58 epigenetic therapies 58 almorexant 58 eritoran 58 Leukine ® 58 NNR Therapeutics 58 Lixivaptan 58 hormone LHRH antagonist 58 milatuzumab 58 elacytarabine 58 MORAb 58 Cloretazine 58 Aurora Kinase 58 C1 INH 57 midstage studies 57 Virulizin ® 57 Phase IIb clinical 57 ADAGIO study 57 amrubicin 57 BRILINTA 57 Everolimus 57 CD# antibody [001] 57 nonclinical studies 57 ATL/TV# 57 temozolomide 57 ALN RSV# 57 INT# [002] 57 SPC# [001] 57 Ecallantide 57 crizotinib PF # 57 erlotinib Tarceva ® 57 desvenlafaxine succinate 57 Sulonex 57 insulin sensitizers 57 bevacizumab Avastin ® 57 Jevtana 57 Onalta 57 Alocrest 57 Elocalcitol 57 highly selective inhibitor 57 Marqibo 57 Relivar 57 TroVax 57 active comparator 57 laquinimod 57 trastuzumab DM1 57 BRIM2 57 pharmacodynamic markers 57 anticancer compound 57 rindopepimut 57 secondary efficacy endpoints 57 Azacitidine 57 opioid induced bowel dysfunction 57 Phase #b/#a clinical 57 carboplatin paclitaxel 57 oral anticancer 57 mTOR inhibitors 57 Avanafil 57 milnacipran 57 ACTEMRA TM 57 Anacetrapib 57 CD# CEA 57 Fodosine 57 TRX1 57 AzaSite Plus 57 Pivotal Phase 57 AeroLEF TM 57 Menerba 57 Candesartan 57 brivaracetam 57 Multiple Ascending Dose 57 ARIKACE ™ 57 Campath alemtuzumab 57 adecatumumab 57 ADP receptor antagonist 57 TAFA# 57 PA# [002] 57 Dyloject TM 57 pitavastatin 57 Phase 2a 57 Voreloxin 57 TNF inhibitor 57 antitumor activity 57 investigational antiplatelet agent 57 Phase 2a clinical 57 HDAC Inhibitor 57 aclidinium bromide 57 VEGF Trap 57 Tezampanel 57 Inhalation Solution 57 OMAPRO 57 albiglutide 57 TNF Tumor Necrosis Factor 57 NV1FGF 57 CBLC# 57 Phase IIIb study 57 fenretinide 57 AAG geldanamycin analog 57 Daclizumab 57 TNFα 57 bifeprunox 57 Teriflunomide 57 imatinib Gleevec ® 57 SinuNase TM 57 CTCE 57 sorafenib tablets 57 PEG INTRON 57 SARMs 57 EPC# 57 Canvaxin 57 Vernakalant 57 aclidinium 57 Onbrez Breezhaler 57 mRCC 57 novel oral anticoagulant 57 senicapoc 57 TORISEL 57 FLT3 57 kinase inhibitors 57 torezolid phosphate 57 LUNESTA 57 registrational 57 RAD# [003] 57 denileukin diftitox 57 dexamethasone Decadron 57 Unit Dose Budesonide 57 Linaclotide 57 Belinostat 57 Afatinib 57 VEGF inhibitor 57 systemic RNAi therapeutic 57 preclinical 57 A3 adenosine receptor 57 Phase 1b clinical 57 Vaprisol 57 multitargeted 57 Atrasentan 57 aprepitant 57 APTIVUS r 57 receptor antagonist 57 Virulizin R 57 R sorafenib tablets 57 Anthim 57 Anavex #-# 57 alemtuzumab 57 compound INCB# 57 CRLX# 57 budesonide 57 cetuximab Erbitux ® 57 tamibarotene 57 uric acid lowering 57 ALKS 57 olmesartan 57 efficacy tolerability 57 Xcytrin 57 Panitumumab 57 JAK3 inhibitor 57 potency selectivity 57 peripherally acting 57 Atiprimod 57 DAPT 57 Satraplatin 57 trial evaluating PRX# 57 asenapine 57 STRIDE PD 57 cetuximab 57 novel anticancer 57 farletuzumab 57 Palifosfamide 57 Catena ® 57 R roscovitine 57 ozarelix 57 Herceptin trastuzumab 57 HDACi 57 IFN α 57 GAMMAGARD LIQUID 57 administered subcutaneously 57 Trexima 57 ofatumumab HuMax CD# 57 Fludara 57 rilonacept 57 afatinib 57 PTK ZK 57 Cetrorelix 57 VitiGam 57 CYC# 57 selective kinase inhibitor 57 Proxinium TM 57 Anturol TM 57 partial agonist 57 Velcade bortezomib 57 Vorinostat 57 BENLYSTA ® 57 CYT# potent vascular disrupting 57 fluticasone furoate 57 ONGLYZA ™ 57 peginesatide 57 Ceflatonin R 57 Personalized Immunotherapy 57 MBP# [001] 57 miR #a [002] 57 Votrient 57 CINQUIL 57 TroVax ® 57 FavId 57 Maximum Tolerated Dose 57 Atacand 57 sargramostim 57 pharmacokinetic PK profile 57 metastatic castration resistant 57 disease modifying 57 LymphoStat B belimumab 57 systemically administered 57 Cerovive 57 ORENCIA ® 57 omacetaxine mepesuccinate 57 ascending dose 57 non alcoholic steatohepatitis 57 rFIXFc 57 CBLB# 57 GLPG# 57 lurasidone 57 Kevetrin ™ 57 ALVESCO HFA 57 chemopreventive agent 57 voreloxin 57 NU# [001] 57 Cloretazine ® 57 ATACAND 57 Telaprevir 57 pharmacokinetic PK study 57 Genasense ® oblimersen 57 XL# XL# XL# XL# 57 Tykerb lapatinib 57 kinase inhibition 57 perifosine 57 Vectibix panitumumab 57 Phase III clinical trials 57 Liposomal 57 ALK inhibitor 57 antibody MAb 57 factor Xa 57 Octreolin 57 GLP toxicology studies 57 #HT# 57 Adentri 57 EDEMA3 trial 57 receptor antagonists 57 BrachySil 57 investigational oral 57 cMET 57 PREOS 57 MYDICAR 57 romiplostim 57 renin inhibitors 57 glucagon receptor 57 NOX E# 57 class mGluR5 inhibitor 57 Zenvia ™ 57 preclinical studies 56 CIMZIA ™ 56 MTP inhibitor 56 DexaSite 56 Cycloset 56 MYDICAR ® 56 tafamidis 56 pegylated liposomal doxorubicin 56 Trofex 56 Acapodene 56 virus HCV protease inhibitor 56 BENICAR HCT 56 Rivaroxaban 56 tesmilifene 56 Phase IIa clinical trials 56 ALN TTR# 56 aripiprazole Abilify 56 Adalimumab 56 Tekamlo 56 Neulasta ® 56 VEGF pathway 56 antithrombotic 56 ranolazine 56 Arimoclomol 56 MT#/MEDI-# 56 Prestara 56 inhibitor RG# 56 Iluvien ® 56 Pharmacokinetics PK 56 Treanda 56 Doxil 56 ocular formulation 56 alemtuzumab Campath 56 linaclotide 56 5 HT3 receptor 56 Bevasiranib 56 EndoTAG 56 eculizumab 56 depsipeptide 56 Cethrin 56 EVIZON TM 56 Aplidin R 56 GRN# 56 bardoxolone 56 dose escalation Phase 56 oral ridaforolimus 56 ANAVEX #-# [001] 56 ONCONASE R 56 Memryte 56 ORENCIA R 56 posaconazole 56 receptor partial agonist 56 tolerability 56 edifoligide 56 lorvotuzumab mertansine 56 Cethromycin 56 ARC# [002] 56 Phase III Clinical Trial 56 evaluating tivozanib 56 eosinophilic asthma 56 IMiDs 56 candesartan cilexetil 56 KB# [002] 56 PEP# [003] 56 serotonin norepinephrine reuptake inhibitor 56 CANCIDAS

Back to home page